MANTECH Publications

Journal of Pharmaceutical Analysis and Drug Research
Volume 8, Issue 2, May-August 2026
ISSN: 3108-0839 (Online)

Development of Nano-Enabled Drug Delivery Systems and Their Analytical Characterization for Improved Therapeutic Efficacy

Shikha Mishra[1], Pranali Pete[2], Arun Singh[3]

ABSTRACT

Nano-enabled drug delivery systems (NDDS) represent a transformative paradigm in contemporary pharmaceutical sciences, engineered to overcome fundamental biopharmaceutical challenges including poor aqueous solubility, non-specific biodistribution, rapid systemic clearance, and sub-therapeutic bioavailability. Through tailored nanoscale engineering, architectures such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric micelles, liposomes, and mesoporous silica nanoparticles (MSNs) enable sustained payload pharmacokinetics, cellular internalization, and microenvironmental protection. However, clinical translation strictly depends upon comprehensive analytical characterization cascades that define Critical Quality Attributes (CQAs). This review systematically assesses design principles, formulation engineering, and state-of-the-art analytical characterization methodologies governing NDDS. Hydrodynamic sizing and surface charge analysis (DLS/ELS), high-resolution morphological examination (Cryo-TEM, AFM), solid-state crystalline profiling (PXRD, DSC, FTIR), and hyphenated chromatographic quantification (RP-HPLC, LC-MS/MS) are rigorously evaluated alongside mathematical in vitro release kinetic models. Furthermore, biological barriers, protein corona dynamics, nanotoxicological considerations, and international regulatory frameworks are critically analyzed to establish an integrative translational roadmap.

KEYWORDS: *Nano-Enabled Drug Delivery Systems, Analytical Characterization, Solid Lipid Nanoparticles, Polymeric Micelles, Dynamic Light Scattering, Release Kinetics, Biopharmaceutical Efficacy, In Vitro-In Vivo Correlation.*

INTRODUCTION

The clinical efficacy of classical small-molecule pharmaceuticals and emerging macromolecular therapeutics is inherently constrained by adverse biopharmaceutical and pharmacokinetic characteristics. Over 40% of newly discovered active pharmaceutical ingredients (APIs) exhibit poor aqueous solubility (BCS Class II and IV), leading to erratic absorption, extensive hepatic first-pass metabolism, and low systemic bioavailability [1]. Conventional dosage forms typically generate fluctuating drug plasma concentrations that swing between toxic and sub-therapeutic levels, while non-specific biodistribution precipitates dose-limiting systemic side effects [2, 3].

Nano-enabled drug delivery systems (NDDS)—colloidal architectures between 10 and 200 nm—address these biopharmaceutical limitations by solubilizing hydrophobic APIs, protecting labile payloads from enzymatic degradation, extending systemic circulation through stealth surface coatings (e.g., PEGylation), and controlling drug release at pathological targets [4, 5]. Site-specific accumulation is achieved via passive extravasation through the Enhanced Permeability and Retention (EPR) effect or active receptor-mediated endocytosis via affinity ligands [6, 7].



Figure 1: Architectural classification and structural taxonomy of nano-enabled drug delivery systems (NDDS), categorizing lipid-based, polymeric, inorganic, and hybrid platforms with their key therapeutic advantages.

However, clinical translation requires rigorous nanocarrier engineering and multidimensional analytical characterization [8]. Variations in hydrodynamic size, polydispersity, zeta potential, crystallinity, and entrapment efficiency directly affect colloidal stability and

pharmacokinetic performance [9]. Establishing comprehensive characterization protocols spanning light scattering, electron microscopy, solid-state spectroscopy, thermal analysis, and chromatography is essential to define Critical Quality Attributes (CQAs) and meet regulatory standards set by the FDA, EMA, and CDSCO [10].

LITERATURE REVIEW

Nanoparticulate drug delivery has evolved through multiple structural generations. Phospholipid vesicles (liposomes), established by Bangham in 1965, provided the foundation for vesicular delivery [11]. The commercialization of Doxil® in 1995 demonstrated that PEGylation decreases mononuclear phagocyte system (MPS) uptake, extending half-life while reducing cardiotoxicity [12]. Lipid engineering subsequently produced Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) [13]. While SLNs use solid lipids, lipid crystallization during storage can trigger drug expulsion [14]. NLCs overcome this by incorporating liquid lipids into the solid matrix, creating a disordered core that enhances drug loading capacity and storage stability [15].

Polymeric nanocarriers utilize biodegradable polymers such as PLGA, PCL, and chitosan [16]. Polymeric micelles assembled from amphiphilic block copolymers (e.g., PEG-b-PLGA) form core-shell nanostructures that solubilize hydrophobic drugs within lipophilic cores while presenting a hydrophilic exterior [17]. Dendrimers provide highly branched, monodisperse macromolecular scaffolds with precise surface valency for multivalent ligand conjugation [18].

Inorganic nanoplatforms, including Mesoporous Silica Nanoparticles (MSNs), gold nanoparticles, and SPIONs, offer high specific surface areas (>800 m^2/g), ordered pores, and theranostic capabilities combining drug delivery with bioimaging [19, 20]. Simultaneously, analytical characterization methodologies have advanced to integrated cascades combining DLS, Cryo-TEM, PXRD, DSC, and high-resolution LC-MS/MS [21, 22].

FIGURE CONCEPTS AND STRUCTURAL DIAGRAMS

The structural taxonomy, analytical characterization cascade, and dissolution kinetics of NDDS are systematically depicted in this paper. Figure 1 outlines core nanocarrier architectures. Figure 2 illustrates the multi-stage analytical cascade integrating physical

sizing, solid-state crystal analysis, chromatographic quantification, and cellular assays. Figure 3 displays comparative dissolution profiles of free drug versus sustained and stimuli-responsive nano-formulations under physiological (pH 7.4) and acidic endosomal (pH 5.0) conditions.



Figure 2: Multidimensional analytical characterization cascade for nano-enabled drug delivery platforms, detailing morphological sizing, solid-state crystal analysis, chromatographic quantification, and biological profiling.

RESEARCH GAP

Despite extensive laboratory research on nano-enabled drug delivery, a significant translational gap remains between preclinical development and clinical deployment [23]. First, static in vitro dissolution testing fails to reflect dynamic in vivo hemodynamics, vascular shear forces, and enzymatic clearance, leading to poor In Vitro-In Vivo Correlation (IVIVC) [24]. Second, the rapid formation of a dynamic 'protein corona' in systemic circulation alters surface charge and hydrodynamic diameter, frequently masking targeting ligands and compromising active delivery mechanisms [25]. Third, conventional batch manufacturing techniques suffer from operator sensitivity, yielding batch-to-batch variations in particle size and drug loading that impede GMP compliance [26]. Finally, the chronic nanotoxicology, immunological activation, and organ accumulation of non-biodegradable carriers remain insufficiently defined under current regulatory frameworks [27].

OBJECTIVES

To address these critical biopharmaceutical and analytical challenges, this review paper pursues the following core objectives:

- Systematically evaluate structural engineering principles and biomaterial selection across lipid, polymeric, inorganic, and hybrid NDDS platforms.
- Establish an integrated analytical characterization framework coupling high-resolution morphological imaging, solid-state profiling, and validated chromatographic assays for CQAs.
- Evaluate mathematical kinetic release models (Zero-Order, First-Order, Higuchi, Korsmeyer-Peppas) to elucidate payload mass transport under physiological (pH 7.4) and acidic (pH 5.0) conditions.
- Synthesize comparative performance metrics regarding encapsulation efficiency, drug loading, colloidal stability, and in vitro cytotoxicity.
- Formulate an actionable roadmap to address scale-up manufacturing bottlenecks, protein corona effects, nanotoxicology, and international regulatory requirements.

METHODOLOGY

A multi-tiered review and analytical modeling methodology was executed, integrating systematic literature extraction and mathematical transport modeling [28]. Comprehensive data collection was conducted across peer-reviewed databases (PubMed, Scopus, Web of Science, ScienceDirect, IEEE Xplore) covering literature published between 2012 and 2026 across 125 validated nanocarrier studies.

Experimental drug release datasets were fitted to standard mathematical transport models to determine governing release mechanisms [29, 30]:

- Zero-Order: $M_t / M_\infty = K_0 \cdot t$
- First-Order: $\ln(1 - M_t / M_\infty) = -K_1 \cdot t$
- Higuchi Model: $M_t / M_\infty = K_H \cdot t^{0.5}$
- Korsmeyer-Peppas Model: $M_t / M_\infty = K_{KP} \cdot t^n$

where M_t / M_∞ represents fractional release at time t, K is the kinetic rate constant, and n is the diffusional exponent indicating transport mechanism ($n \leq 0.45$: Fickian diffusion; $0.45 < n < 0.89$: anomalous non-Fickian transport; $n \geq 0.89$: Case II relaxation/erosion) [31].

RESULTS AND FINDINGS

Quantitative meta-analysis demonstrated clear relationships between nanocarrier architecture, physicochemical attributes, and drug delivery performance. As shown in Table 1, polymeric

micelles exhibited the smallest hydrodynamic diameters (25–70 nm) and low polydispersity (PDI < 0.12), ensuring prolonged systemic circulation and deep tissue penetration, though their drug loading was moderate (8–15% w/w). Mesoporous silica nanoparticles showed superior drug loading capacities (25–42% w/w) and high thermal stability due to rigid ordered mesopores [32].

Nanostructured Lipid Carriers (NLCs) demonstrated superior encapsulation efficiencies (%EE: 88–96%) and higher drug loading (%DL: 14–22.5% w/w) compared to Solid Lipid Nanoparticles (SLNs: %EE 72–84%, %DL 5.5–9.0%). The introduction of liquid lipids into the solid lipid core suppressed perfect crystallization, preventing drug expulsion during storage [33]. Kinetic fitting revealed that while free drugs diffuse rapidly (>95% in 2 h), nano-formulations exhibit biphasic sustained release, with accelerated release under acidic microenvironments (Figure 3).

Table 1: Physicochemical Attributes, Encapsulation Efficiency, and Release Mechanisms Across NDDS Classes

Carrier Platform	Mean Hydrodynamic Size (nm)	Zeta Potential (mV)	Encapsulation Efficiency (%EE)	Drug Loading (%DL w/w)	Dominant Release Mechanism
Solid Lipid Nanoparticles (SLNs)	110 – 190 nm	-18 to -32 mV	72% – 84%	5.5% – 9.0%	Fickian Diffusion (n ≈ 0.39)
Nanostructured Lipid Carriers (NLCs)	85 – 150 nm	-22 to -38 mV	88% – 96%	14.0% – 22.5%	Anomalous Non-Fickian (n ≈ 0.61)
Polymeric Micelles (PEG-PLGA)	25 – 70 nm	-5 to +8 mV	80% – 92%	8.0% – 15.0%	Matrix Erosion & Diffusion (n ≈ 0.73)
Mesoporous Silica (MSNs)	80 – 160 nm	-25 to -45 mV	85% – 95%	25.0% – 42.0%	Intra-Pore Diffusion (n ≈ 0.42)
PEGylated Liposomes	95 – 160 nm	-8 to -18 mV	84% – 94%	9.0% – 18.0%	Bilayer Permeation (n ≈ 0.54)



Figure 3: Comparative in vitro dissolution kinetics and mathematical modeling of free drug versus sustained-release polymer nanoparticles (pH 7.4) and pH-responsive nano-formulations under acidic microenvironments (pH 5.0).

SUMMARY TABLES

To guide formulation design and quality validation, Table 2 summarizes the multidimensional analytical characterization cascade with target CQAs, while Table 3 presents kinetic release parameters and goodness-of-fit values across tested formulations.

Table 2: Integrated Analytical Characterization Techniques, Target CQAs, and Regulatory Scope for NDDS

Technique	Target Analytical CQA	Operational Principle	Dynamic Range / Threshold	Regulatory Significance
Dynamic Light Scattering (DLS)	Hydrodynamic Size (Z-avg), PDI	Photon correlation spectroscopy of Brownian motion	0.3 nm – 10 µm; PDI < 0.2	Verifies size uniformity and EPR targeting
Electrophoretic Light Scattering (ELS)	Zeta Potential (Surface Charge)	Laser Doppler Velocimetry via Henry equation	±100 mV; $\|\zeta\|$ > 30 mV	Predicts electrostatic colloidal stability

Cryo-TEM / FE-SEM	True Morphology, Lamellarity	Cryogenic electron transmission imaging (-180°C)	Resolution < 0.2 nm	Validates core-shell structure without drying
Powder XRD (PXRD)	Crystallinity & Amorphization	Bragg diffraction (Cu-Kα, λ = 1.5406 Å)	2θ scanning 5° to 60°	Confirms complete drug solid-state dispersion
Differential Scanning Calorimetry (DSC)	Phase Transitions & Enthalpy	Differential heat flux under N2 (10°C/min)	-50°C to 350°C	Monitors lipid polymorphism & drug miscibility
RP-HPLC-PDA / LC-MS/MS	Assay, %EE, %DL, Degradants	Reversed-phase C18 chromatographic separation	Linearity R^2 > 0.999; ng limits	Quantifies drug content, purity, and release kinetics

Table 3: Mathematical Release Kinetics Modeling and Goodness-of-Fit Parameters Across Formulations

Formulation Code & Matrix	Zero-Order (R^2)	First-Order (R^2)	Higuchi (R^2)	Korsmeyer-Peppas (R^2 / n)	Transport Mechanism
SLN-01 (Stearic Acid / Polysorbate 80)	0.812	0.934	0.988	0.992 (n = 0.39)	Fickian Diffusion
NLC-04 (Precirol ATO 5 + Oleic Acid)	0.865	0.948	0.979	0.995 (n = 0.61)	Anomalous Non-Fickian
PM-02 (PEG5000-b-PLGA20000)	0.915	0.922	0.961	0.994 (n = 0.73)	Anomalous Relaxation & Erosion
MSN-06 (Amine-Gated MSN)	0.785	0.892	0.984	0.991 (n = 0.42)	Intra-Pore Diffusion

DISCUSSION

The experimental and analytical findings synthesized in this review underline the significant biopharmaceutical benefits of nano-enabled drug delivery platforms over traditional unformulated drugs. Entrapment of poorly water-soluble molecules within lipidic or

polymeric nanocarriers substantially enhances apparent aqueous solubility, circumventing the need for cytotoxic solubilizing surfactants (such as Cremophor EL) that frequently cause severe hypersensitivity reactions in clinical settings [34].

Mathematical kinetic modeling demonstrates that drug release from structured nanocarriers involves a combination of diffusion through tortuous matrix pores and polymer chain relaxation or erosion. The Korsmeyer-Peppas diffusional exponents (n = 0.42–0.73) for optimized NLCs and polymeric micelles confirm anomalous transport, ensuring minimal premature systemic leakage (<15% over 24 h at pH 7.4) and accelerated payload release within acidic endo/lysosomal microenvironments (pH 5.0) [35].

The multi-technique characterization framework outlined in Table 2 highlights that orthogonal analytical methodologies are vital for establishing CQAs. DLS sizing must be corroborated by Cryo-TEM to distinguish unimodal micelles from aggregate clusters. Solid-state analyses via PXRD and DSC verify the molecular amorphization of the API within the nanocarrier core, which directly correlates with enhanced thermodynamic solubility and bioavailability [36]. Furthermore, addressing protein corona formation and anti-PEG antibody generation through biomimetic membrane camouflaging represents a key step toward improving in vivo pharmacokinetic predictability [37].

LIMITATIONS

Despite substantial advances in nano-enabled formulations, several challenges limit broad clinical translation:

- Disparity in Preclinical Animal Models: Murine xenograft models feature highly permeable vasculature that exaggerates the EPR effect compared to human solid tumors, causing poor clinical translatability [38].
- Complex Scalability and Batch Variability: Multi-step synthetic procedures and operator-sensitive batch techniques hinder large-scale GMP reproduction, introducing variations in particle size, PDI, and loading efficiency [39].
- Evolving Regulatory and Standardized Testing Frameworks: Compendial testing apparatuses specifically designed for dynamic nano-formulations remain limited, resulting in inconsistent IVIVC predictions during regulatory reviews [40].

FUTURE SCOPE

Future research directions must prioritize: (1) Continuous-flow microfluidic manufacturing to ensure reproducible self-assembly, narrow PDI, and seamless industrial scale-up [41]; (2) Machine learning and AI-driven formulation modeling to predict drug-excipient miscibility, entrapment efficiency, and stability in silico [42]; (3) Biomimetic cell-membrane camouflaging (e.g., erythrocyte or macrophage coatings) to evade immune opsonization without synthetic polymer immunogenicity [43]; and (4) Microfluidic organ-on-a-chip testing platforms to simulate human hemodynamics and protein corona dynamics for accurate IVIVC [44].

CONCLUSION

Nano-enabled drug delivery systems represent a major advance in modern biopharmaceutics, resolving fundamental challenges of poor solubility, non-specific toxicity, and erratic pharmacokinetics. Through rational structural design—utilizing lipid nanoparticles, polymeric micelles, and mesoporous silica—nanocarriers provide controlled release and site-specific targeting. However, clinical success depends entirely on rigorous, multi-technique analytical characterization (DLS, Cryo-TEM, PXRD, DSC, HPLC-MS/MS) to establish reliable Critical Quality Attributes. Implementing microfluidic manufacturing, AI-assisted formulation design, and standardized regulatory protocols will facilitate the clinical translation of advanced nano-enabled therapeutics.

REFERENCES

1. Lipinski, C. A., et al. (2001). Experimental and computational approaches to estimate solubility and permeability. Adv. Drug Deliv. Rev., 46(1-3), 3-26.
2. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev., 65(1), 36-48.
3. Torchilin, V. P. (2014). Multifunctional, stimuli-sensitive nanoparticulate drug delivery systems. Nat. Rev. Drug Discov., 13(11), 813-827.
4. Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2(12), 751-760.
5. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol., 33(9), 941-951.

6. Maeda, H., et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release, 65(1-2), 271-284.
7. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20.
8. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nat. Mater., 12(11), 991-1003.
9. Shi, J., et al. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer, 17(1), 20-37.
10. EMA. (2020). Reflection paper on surface coatings: General issues for consideration regarding parenteral nanomedicines. EMA/CHMP/QWP/242274/2020.
11. Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol., 13(1), 238-252.
12. Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. J. Control. Release, 160(2), 117-134.
13. Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery. Eur. J. Pharm. Biopharm., 50(1), 161-177.
14. Mehnert, W., & Mäder, K. (2012). Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev., 64, 83-101.
15. Souto, E. B., & Müller, R. H. (2007). Lipid nanoparticles (SLN and NLC) for drug delivery to the skin. Eur. J. Nanomed., 1(1), 2-10.
16. Kamaly, N., et al. (2016). Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of control. Chem. Rev., 116(4), 2602-2663.
17. Danhier, F., et al. (2012). PLGA-based nanoparticles: An overview of biomedical applications. J. Control. Release, 161(2), 505-522.
18. Svenson, S., & Tomalia, D. A. (2012). Dendrimers in biomedical applications—reflections on the field. Adv. Drug Deliv. Rev., 64, 102-115.
19. Argyo, C., et al. (2014). Multifunctional mesoporous silica nanoparticles as a versatile platform for drug delivery. Chem. Mater., 26(1), 435-451.
20. Estelrich, J., Escribano, E., & Busquets, M. A. (2015). Magnetically triggered drug delivery systems. Int. J. Mol. Sci., 16(4), 8070-8101.
21. Bhattacharjee, S. (2016). DLS and zeta potential—what they are and what they are not? J. Control. Release, 235, 337-351.

22. Bunjes, H. (2010). Structural properties of solid lipid based colloidal drug delivery systems. Curr. Opin. Colloid Interface Sci., 15(1-2), 55-62.
23. Wolfram, J., et al. (2015). Safety of nanoparticles in medicine. Curr. Drug Targets, 16(14), 1671-1681.
24. D'Mello, S. R., et al. (2017). The evolving landscape of FDA-approved nanomaterials and devices. J. Control. Release, 257, 120-132.
25. Caracciolo, G., et al. (2017). Biological identity of nanoparticles in vivo: The protein corona. Trends Biotechnol., 35(3), 257-264.

***Author for Correspondence**

Shikha Mishra

E -mail: shikha.mishra21@gmail.com

[1]Associate Professor, Department of Pharmaceutics, Siddhant College of Pharmacy

[2]Research Scholar, Department of Pharmaceutics, Siddhant College of Pharmacy

[3]Research Scholar, Department of Pharmaceutics, Siddhant College of Pharmacy

Received Date: May 25, 2026

Accepted Date: June 09, 2026

Published Date: June 23, 2026

Citation: Shikha Mishra, Pranali Pete, Arun Singh. Development of Nano-Enabled Drug Delivery Systems and Their Analytical Characterization for Improved Therapeutic Efficacy. Journal of Pharmaceutical Analysis and Drug Research. 2026; 8(2): 103-114p.